Italia markets close in 4 hours 10 minutes

Abiomed, Inc. (ABMD)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
330,60+0,63 (+0,19%)
Alla chiusura: 4:00PM EDT

330,80 0,20 (0,06%)
Preborsa: 7:00AM EDT

Abiomed, Inc.

22 Cherry Hill Drive
Danvers, MA 01923
United States
978 646 1400
http://www.abiomed.com

Settore/iHealthcare
SettoreMedical Devices
Impiegati a tempo pieno1.536

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Michael R. MinogueChairman, CEO & Pres1,68MN/D1967
Mr. Todd A. TrappCFO & VP800,98kN/D1971
Dr. David M. WeberSr. VP & COO752,48k771,2k1961
Mr. Michael G. HowleyVP & GM of Global Sales522,56kN/D1964
Mr. Andrew J. GreenfieldVP & Chief Commercial Officer547,39kN/D1973
Dr. Thorsten Siess Ph.D.VP & CTON/DN/DN/D
Ms. Ingrid Goldberg WardDirector of Investor RelationsN/DN/DN/D
Mr. Marc A. BeganVP, Gen. Counsel & Sec.N/DN/D1967
Sarah KarrCommunications Mang.N/DN/DN/D
Ms. Karen MahoneyHead of Global HRN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Abiomed, Inc. al 1 aprile 2021 è 10. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 10; diritti degli azionisti: 10; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.